Frequently Asked Questions about KalVista Pharmaceuticals, Inc. (KALV)

Name: KalVista Pharmaceuticals, Inc. (KALV) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does KalVista Pharmaceuticals, Inc. (KALV) do?

Accepted Answer

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HA...

Question 2

Is KalVista Pharmaceuticals, Inc. (KALV) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of KALV reveals an Altman Z-Score of -1.81 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if KALV fits their risk profile.

Question 3

What is the current P/E ratio for KALV?

Accepted Answer

As of the latest trading session, KalVista Pharmaceuticals, Inc. (KALV) has a trailing P/E ratio of -6.08.

Question 4

Who is the CEO of KalVista Pharmaceuticals, Inc.?

Accepted Answer

The current Chief Executive Officer of KalVista Pharmaceuticals, Inc. is Benjamin L. Palleiko.

Question 5

What was KALV's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, KalVista Pharmaceuticals, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does KALV pay a dividend?

Accepted Answer

KalVista Pharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does KALV have?

Accepted Answer

In its latest reporting period, KalVista Pharmaceuticals, Inc. generated $-0.15B in Free Cash Flow against a total debt load of $0.01B.

Question 8

What is the Price-to-Book (P/B) ratio of KalVista Pharmaceuticals, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for KalVista Pharmaceuticals, Inc. (KALV) is currently -375.06.

Question 9

What is the Price-to-Sales (P/S) ratio of KALV?

Accepted Answer

Based on trailing twelve-month data, KalVista Pharmaceuticals, Inc. (KALV) trades at a Price-to-Sales (P/S) ratio of 13.73.

Question 10

What is KalVista Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Accepted Answer

KalVista Pharmaceuticals, Inc. (KALV) has a Return on Equity (ROE) of -444.41%, representing its profitability relative to shareholder equity.